SkyLabs' Cuffless Blood Pressure Monitor Gains Traction in Major Hospitals

By StartupKorea Business Desk | Jun 08, 2026

SkyLabs' Innovative Device Achieves Significant Adoption Rate

SkyLabs, a promising startup in the medical technology sector, has made remarkable strides with its cuffless blood pressure monitor, the CART BP Pro. Recent reports indicate that the device has been adopted by 38 major hospitals in South Korea, which represents an impressive 81% of the country’s top-tier medical institutions.

Transforming Blood Pressure Monitoring

The CART BP Pro is currently being utilized in a total of 1,920 healthcare facilities across the nation, including general hospitals and clinics, just 18 months after its launch. This rapid adoption can be attributed to the limitations of traditional ambulatory blood pressure monitoring (ABPM) methods, which often cause discomfort to patients due to prolonged upper arm cuff inflation, disrupting their daily activities and sleep.

Medical professionals have recognized the necessity for continuous blood pressure monitoring but have hesitated to recommend it due to patient discomfort. The CART BP Pro addresses this issue by allowing users to simply wear a ring on their finger, which automatically records blood pressure without causing any discomfort or disruption to their daily lives. This ease of use has led to a reduction in patient resistance, enabling healthcare providers to confidently recommend 24-hour blood pressure monitoring.

Furthermore, the data collected by the CART BP Pro aids in personalized medication prescriptions and diagnoses, significantly enhancing patient care.

Endorsements and Clinical Validation

SkyLabs has also received institutional recognition from the Korean Society of Hypertension, which has amended its 2026 hypertension management guidelines to officially allow the use of verified cuffless blood pressure monitors in clinical practice. This endorsement underscores the clinical efficacy of the CART BP Pro, as it can capture critical data such as nighttime blood pressure, morning hypertension, and blood pressure variability—metrics that were challenging to obtain with traditional methods.

With the clinical effectiveness of the CART BP Pro validated through partnerships with local healthcare professionals, SkyLabs is now poised to expand its reach into international markets. CEO Lee Byung-hwan expressed confidence in the product's performance, stating, “The adoption and prescription expansion of the CART BP Pro in major hospitals serves as an objective indicator of its clinical efficacy. We aim to increase our market share on the global stage.”

This expansion into global markets reflects SkyLabs' ambition to leverage its innovative technology to improve healthcare outcomes worldwide.

Source: Platum. This is an original English briefing based on the cited report.